Section 2: Pluripotency and the Undifferentiated State

An aspect unique to human pluripotent stem cells (hPSCs) is their undifferentiated developmental state and the potential to give rise to all somatic lineages. In working with hPSCs, these defining features should be rigorously demonstrated not only for newly derived lines, new culture systems and genetically modified lines, but also for experimentation with more established lines to ensure the cells are behaving as expected.

With mouse ES cells, pluripotency has ultimately been demonstrable by the ability of the cells to participate in development and form germ line chimeras when transferred to a blastocyst that is allowed to develop to term. For obvious ethical reasons such a test is not possible for hPSCs, so pluripotency has to be demonstrated by surrogate assays – either the ability to form teratomas containing tissues of all three germ layers when allowed to form xenograft tumors, or by differentiation in vitro. Human PSCs typically express a number of particular

genes and cell surface antigens that can be used to monitor the differentiation of these cells. However, none of these markers are uniquely associated with pluripotent differentiation capacity, and many are also expressed by stem cells that have lost the capacity to differentiate, (referred to as “nullipotent” stem cells). Thus, these markers cannot be used to identify pluripotent cells in the absence of functional evidence of pluripotency and further, they should not be referred to as ‘pluripotency markers,’ but as markers of the undifferentiated state.

As the field has grown, especially following the development of hiPSCs, the rigor and reproducibility of research has been hampered by imprecise reporting of experiments and confusion in terminology. In this section we provide clear guidance on how human pluripotent stem cells should be defined and characterized, to ensure accurate and unambiguous reporting of results obtained with these cells.

Assessing Pluripotency

Recommendation 2 .1 .1: Pluripotency in human cells should be demonstrated experimentally by assays that assess differentiation capacity . Differentiation should be shown by quantitative measurements of the induction of marker combinations representative of ectoderm, endoderm, and mesoderm lineages, alongside loss of markers of the undifferentiated state.

Pluripotency is a functional property implying the capacity of a single cell to differentiate into all the somatic cell types of an organism. A cell line should be designated as pluripotent only if it has been experimentally shown to be capable of differentiating into cells representing all three embryonic germ layers that give rise to the somatic lineages of a developing organism. Human PSCs may exhibit a bias in the lineage(s) generated but should be able to make ectoderm, definitive endoderm, and mesoderm without genetic or epigenetic manipulation. Typically, hPSCs also have potential to produce primordial germ cells, but this feature may be absent in later stages of pluripotency. They also may or may not be capable of contributing to chimeras, but such capacity is not an essential part of the definition.

To claim differentiation into specific lineages or cell types, in vitro assays are recommended. For pluripotency designation, unequivocal evidence should be presented of differentiation into progenitors of definitive endoderm, mesoderm and neuroectoderm. Preferably, evidence of further differentiation into lineage-specific cell types should also be provided. The efficiency and extent of differentiation into cells of each germ layer should be reported (see Section 5).

Evidence of differentiation should be based upon multiple criteria, which may include morphology, expression of appropriate combinations of lineage or cell type specific mRNAs or proteins, cell surface markers, and assessment of functional properties. Additionally, ultrastructural features, multi-’omics profiling and transgenic reporters may be used where feasible. There should also be downregulation of markers of undifferentiated cells. Examples of markers that have been widely used to monitor differentiation are provided in Appendix 4 (Tables A4.1, A4.2, and A4.3). Where possible, marker expression should be quantified by techniques such as flow cytometry or quantitative imaging.

The degree of stringency required for determination of undifferentiated stem cell status and differentiation potential depends on the context of the experiments reported and the conclusions drawn from them (see Figure 2, below).

Figure 2. The status and purpose of hPSC lines influence the characterization of the undifferentiated state and pluripotency potential. hPSC lines that have been previously published (left column) require less characterization than new lines or new culture or reprogramming systems (right column)

Recommendation 2 .1 .1 .a: For studies using cell lines where pluripotency has been established as described above and reported in peer-reviewed publications, it may not be necessary to repeat multi-lineage differentiation assays . Minimally, however, the undifferentiated status of the cells should be monitored by quantitative marker analysis (see Table A4 .1).

Recommendation 2 .1 .1 .b: For large scale studies describing the derivation of extensive panels of new pluripotent cell lines by well-established techniques, where in depth characterization of all lines may not be possible, a subset of the lines should be confirmed to be pluripotent by differentiation assays . For the remaining lines, the undifferentiated status of the cells should be monitored by quantitative marker analysis; these lines should then be designated putative pluripotent lines.

Recommendation 2 .1 .1 .c: Where novel reprogramming techniques, cell culture methodologies, or other non-established protocols are used, confirmation of the undifferentiated status and developmental potential should be comprehensive . These include evaluation of larger panels of markers of the undifferentiated state and the capacity for differentiation into progenitors of the three embryonic germ layers, and of more differentiated cells, by multiparametric analysis.

Recommendation 2 .1 .2: Xenograft (teratoma) assays are not required to indicate pluripotency.

Although xenografting of pluripotent stem cells into immunocompromised animals provides a strong test of pluripotency and has been widely used in the past, concerns for animal welfare and increasing regulation in different jurisdictions make this assay undesirable if equivalent information can be derived from in vitro assays. The xenograft assay can provide evidence of the ability of differentiated cells to undergo histogenesis to yield complex tissues. However, several studies have confirmed that adequate evidence for pluripotency can be obtained from in vitro differentiation (Allison et al., 2018; Bock et al., 2011). Organoid or 3D assays in vitro may yield information on capacity for morphogenesis and histogenesis. Thus, xenograft assays are not recommended as a routine method for assessing pluripotency, although they may be a useful adjunct for the assessment of potential malignancy. If xenograft assays are used, criteria for assessment of teratomas and teratocarcinomas are described in Appendix 4.

The Undifferentiated State

Recommendation 2 .2 .1: The expression of recognized cell surface markers and transcripts can be used to assess and monitor the undifferentiated status of a cell line . However, the expression of such markers does not demonstrate pluripotency.

None of the markers present on undifferentiated cells are uniquely expressed in these cells, although they are often incorrectly used to identify pluripotent stem cells. Equally, there are many examples of cells that have little or no capacity for differentiation, notably nullipotent embryonal carcinoma cells from germ cell tumors, but that express many of these markers of undifferentiated cells, including OCT4 (POU5F1) and NANOG (see Table A4.1, for a list of markers). Therefore, these markers should not be called pluripotency markers as pluripotency cannot be defined by marker expression from undifferentiated cells. Nevertheless, such markers and gene expression profiles are useful to indicate undifferentiated status and as surrogate measures for retention of identity in cell types whose pluripotency has been well-established by prior differentiation assays, e.g., conventional hESCs or hiPSCs. They may also be used to screen putative pluripotent cells created by well-established methods for producing pluripotent cells. The absence of certain key markers, e.g., OCT4, can be strong indicators of loss of pluripotency, but these data cannot be considered definitive.

Developmental State

Recommendation 2 .3 .1: Evidence that a stem cell culture represents a particular developmental state should be based on relatedness to a stage and region of embryo development as assessed by specific gene expression and as far as possible by global profiling . Developmental state should be corroborated by demonstration of appropriate lineage-specific differentiation, including potential lineage biases . Profiling comparisons need to clarify the relationship to other reported stem cell states, and information should be provided on differentiation or interconversion between states . The culture conditions for generating and propagating the specific stem cell state should be reported in full, together with information on stability (or transience), homogeneity/heterogeneity and clonogenicity.

Stem cells in culture are expected to correspond to staging points along the developmental trajectory in the embryo between zygote and late gastrulation. Such correspondence means high global similarity in transcriptome and epigenome together with relatedness in features such as cell morphology, metabolic parameters, and differentiation competence.

Epiblast cells in the preimplantation human embryo and corresponding pluripotent stem cell lines are designated naïve. Naïve pluripotency is considered a discrete state. It is succeeded by an intermediate or formative stage of pluripotency that has shed naïve characteristics but not gained lineage specification. The formative phase appears to last several days in humans, and it is probable that a series of formative sub-states may be captured in culture. Formative pluripotency is a continuum with regionally specified and fated epiblast at the time of gastrulation, termed primed. Studies with mouse epiblast stem cells (EpiSCs) demonstrate that primed pluripotent stem cells can reside in different sub-states, related to different regions of gastrulation stage epiblast.

While cells in culture cannot be completely identical to cells in vivo, it should be considered that adaptations to the culture environment may induce features and identities that do not exist in the embryo. Stem cell properties that are discordant with those known for cells in the embryo should be declared. These aberrant pluripotent states may be of interest for certain applications, but caution is required in interpretations related to normal development.

Recommendation 2 .3 .1 .a: Heterogeneity within the culture should be quantitatively addressed at the single cell level, by flow cytometry, high content screening, live cell imaging, and/or single cell -omics . Composition of the cultures should be assessed at multiple time points . Ideally, sub-populations should be characterized for inter- conversion and for clonogenic potential.

Pluripotent stem cell cultures are often mixed in composition. Such heterogeneity may arise in several ways including: continuous differentiation of a fraction of cells; maintenance of different pluripotent states in the same culture conditions; hierarchical pluripotency progression with more primitive naïve or formative stage cells giving rise to later stages; interconversions between pluripotent sub-states reflecting inherent plasticity but not necessarily relevant to developmental events; and spread of genetic or epigenetic changes that influence cell identity.

The ISSCR's Standards for Human Stem Cell Use in Research are strictly copyrighted by the society. No part of this document may be produced in any form without written permission of The International Society for Stem Cell Research. Contact isscr@isscr.org for more information.

©2023 by The International Society for Stem Cell Research. All rights reserved.

Previous
Previous

Section 1: Basic Characterization

Next
Next

Section 3: Genomic Characterization